- Conditions
- Type 1 Diabetes Mellitus
- Interventions
- Siplizumab
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 8 Years to 45 Years
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 5
- States / cities
- Aurora, Colorado • Iowa City, Iowa • New York, New York + 2 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 625–648
of 8,003
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Stimulant Overdose
- Interventions
- Aim 1 (case-cohort study), Aim 2 (case-crossover study), Aim 3 (cohort study)
- Other
- Lead sponsor
- University of Pennsylvania
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 634,939 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2025
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Respiratory Syncytial Virus (RSV)
- Interventions
- RSV vaccine
- Biological
- Lead sponsor
- University of Rochester
- Other
- Eligibility
- 60 Years and older
- Enrollment
- 152 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2024
- U.S. locations
- 1
- States / cities
- Rochester, New York
- Conditions
- Advanced Solid Tumor
- Interventions
- RP3, Nivolumab
- Biological
- Lead sponsor
- Replimune, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 123 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2026
- U.S. locations
- 3
- States / cities
- Iowa City, Iowa • Pittsburgh, Pennsylvania • Houston, Texas
- Conditions
- Fragile X Syndrome
- Interventions
- AFQ056
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 3 Years to 11 Years
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2013
- U.S. locations
- 3
- States / cities
- Sacramento, California • Chicago, Illinois • Nashville, Tennessee
- Conditions
- X-linked Hypohidrotic Ectodermal Dysplasia
- Interventions
- EDI200
- Drug
- Lead sponsor
- Edimer Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 40 Years
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2013
- U.S. locations
- 2
- States / cities
- San Francisco, California • Cincinnati, Ohio
- Conditions
- Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Metastatic Head and Neck Squamous Cell Carcinoma, Metastatic Hypopharyngeal Squamous Cell Carcinoma, Metastatic Laryngeal Squamous Cell Carcinoma, Metastatic Nasopharyngeal Squamous Cell Carcinoma, Metastatic Oral Cavity Squamous Cell Carcinoma, Metastatic Oropharyngeal Squamous Cell Carcinoma, Metastatic Sinonasal Squamous Cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma, Recurrent Hypopharyngeal Squamous Cell Carcinoma, Recurrent Laryngeal Squamous Cell Carcinoma, Recurrent Nasopharyngeal Squamous Cell Carcinoma, Recurrent Oral Cavity Squamous Cell Carcinoma, Recurrent Oropharyngeal Squamous Cell Carcinoma, Recurrent Sinonasal Squamous Cell Carcinoma, Squamous Cell Carcinoma of Unknown Primary, Stage IV Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8, Stage IV Hypopharyngeal Carcinoma AJCC v8, Stage IV Laryngeal Cancer AJCC v8, Stage IV Lip and Oral Cavity Cancer AJCC v8, Stage IV Nasopharyngeal Carcinoma AJCC v8, Stage IV Oropharyngeal (p16-Negative) Carcinoma AJCC v8, Stage IV Sinonasal Cancer AJCC v8
- Interventions
- Autologous Tumor Membrane Vesicles Vaccine, Biospecimen Collection, Computed Tomography, Echocardiography, Magnetic Resonance Imaging, Pembrolizumab, Positron Emission Tomography, Surgical Procedure
- Biological · Procedure
- Lead sponsor
- Emory University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 2
- States / cities
- Atlanta, Georgia
- Conditions
- Metastatic Colorectal Cancer
- Interventions
- Atezolizumab, Cobimetinib
- Biological · Drug
- Lead sponsor
- Niharika Mettu
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2025
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Myocardial Infarction
- Interventions
- NX-CP105
- Drug
- Lead sponsor
- Neuronyx
- Industry
- Eligibility
- 30 Years to 75 Years
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2006
- U.S. locations
- 5
- States / cities
- Phoenix, Arizona • La Jolla, California • Chicago, Illinois + 2 more
- Conditions
- Mantle Cell Lymphoma
- Interventions
- Acalabrutinib, Lenalidomide, Rituximab, Obinutuzumab
- Drug
- Lead sponsor
- Weill Medical College of Cornell University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 37 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2028
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- MASH, MASH - Metabolic Dysfunction-Associated Steatohepatitis
- Interventions
- Resmetirom
- Drug
- Lead sponsor
- Madrigal Pharmaceuticals, Inc.
- Industry
- Eligibility
- 6 Years to 17 Years
- Enrollment
- 61 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 1
- States / cities
- Indianapolis, Indiana
- Conditions
- Cancer, Solid Tumor Cancer, Advanced Metastatic Cancer, Prostate, Small Cell Lung Cancer, Ovarian Cancer, Breast Cancer
- Interventions
- SYS6043
- Drug
- Lead sponsor
- Conjupro Biotherapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 386 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 5
- States / cities
- Plantation, Florida • Austin, Texas • San Antonio, Texas + 1 more
- Conditions
- Cervical Cancer, Advanced Cervical Carcinoma, Metastatic Cervical Cancer, Metastatic Cervical Carcinoma, Recurrent Cervical Carcinoma
- Interventions
- Dostarlimab, Cobolimab
- Drug
- Lead sponsor
- Meghan Shea
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 66 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 2
- States / cities
- Boston, Massachusetts
- Conditions
- Estimating Infant Food Intake
- Interventions
- Not listed
- Lead sponsor
- Pennington Biomedical Research Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 75 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2012 – 2014
- U.S. locations
- 1
- States / cities
- Baton Rouge, Louisiana
- Conditions
- Melanoma, Thyroid Cancer, Colorectal Cancer, Non-small Cell Lung Cancer, Cholangiocarcinoma, Histiocytosis, Hairy Cell Leukemia
- Interventions
- PLX8394
- Drug
- Lead sponsor
- Fore Biotherapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2015
- U.S. locations
- 3
- States / cities
- Scottsdale, Arizona • Salt Lake City, Utah • Spokane, Washington
- Conditions
- Hepatic Impairment
- Interventions
- PF-07321332, Ritonavir
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 17 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021
- U.S. locations
- 2
- States / cities
- Tustin, California • Saint Paul, Minnesota
- Conditions
- Multiple Sclerosis
- Interventions
- Ublituximab, Placebo
- Biological · Drug
- Lead sponsor
- TG Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 49 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2018
- U.S. locations
- 12
- States / cities
- Phoenix, Arizona • Pasadena, California • Torrance, California + 9 more
- Conditions
- Tuberculosis
- Interventions
- TBA-354, Placebo
- Drug · Other
- Lead sponsor
- Global Alliance for TB Drug Development
- Other
- Eligibility
- 19 Years to 50 Years
- Enrollment
- 48 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015
- U.S. locations
- 1
- States / cities
- Lincoln, Nebraska
- Conditions
- Colorectal Cancer, Lung Cancer, Breast Cancer, Prostate Cancer
- Interventions
- Ad5 CEA Vaccine
- Biological
- Lead sponsor
- NantCell, Inc.
- Industry
- Eligibility
- 21 Years to 75 Years
- Enrollment
- 43 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2017
- U.S. locations
- 2
- States / cities
- Durham, North Carolina • Spokane, Washington
- Conditions
- Healthy
- Interventions
- PF-06260414, Placebo
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 21 Years to 50 Years · Male only
- Enrollment
- 72 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014 – 2015
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
- Conditions
- CANCER,NOS
- Interventions
- Lirilumab, Nivolumab, Ipilimumab
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 337 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2019
- U.S. locations
- 16
- States / cities
- San Francisco, California • Ocala, Florida • Chicago, Illinois + 11 more
- Conditions
- Morbid Obesity, Metabolic Syndrome, Diabetes Mellitus, Hypertension, Obstructive Sleep Apnea of Adult
- Interventions
- GLP-1 receptor agonist
- Drug
- Lead sponsor
- University of Missouri-Columbia
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2030
- U.S. locations
- 1
- States / cities
- Columbia, Missouri
- Conditions
- Carcinoma, Renal Cell, Renal Cell Carcinoma of Papillary Histology, Renal Cell Carcinoma With Clear Cell Histology, Renal Cell Carcinoma With Non-Clear Cell Histology
- Interventions
- AGS-16C3F
- Drug
- Lead sponsor
- Agensys, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 34 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2017
- U.S. locations
- 5
- States / cities
- Ann Arbor, Michigan • Detroit, Michigan • Buffalo, New York + 2 more
- Conditions
- Hemorrhagic Fever, Ebola
- Interventions
- HPIV3-EbovZ GP Vaccine
- Biological
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015 – 2016
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland